Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals held its 32nd Annual General Meeting on September 30, 2025 via video conferencing, where all 5 ordinary resolutions were passed with near-unanimous approval. The resolutions included adoption of audited financial statements for FY2024-25, declaration of a final dividend, re-appointment of Executive Director Mr. Dhruvin Shah (DIN: 08801616), and appointment of statutory and secretarial auditors (the latter for a 5-year term). Out of 21,576 total shareholders, only 47 attended (7 promoter group and 40 public), and voting turnout was extremely low at just 2.24% of outstanding shares (97,87,162 shares voted out of 43,78,79,440). The final dividend resolution saw 99.99% approval with just 221 shares voted against, while all other resolutions received 100% approval.
Routine AGM clearance with all resolutions passed smoothly. The final dividend for FY2024-25 has been formally approved by shareholders. However, the very low voting participation (2.24%) signals weak retail shareholder engagement, though this is common in small-cap companies with concentrated promoter holdings.